Skip to main content
SupplementScience

Probiotics (Lactobacillus) Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Strong

Lactobacillus is the most extensively studied probiotic genus with thousands of clinical trials. The evidence base is strongest for L. rhamnosus GG (AAD prevention, pediatric diarrhea), L. plantarum 299v (IBS), L. reuteri DSM 17938 (infantile colic), and L. acidophilus (lactose digestion). A critical principle is strain specificity — clinical benefits are tied to specific strains, not the genus as a whole. The AGA conditionally recommends L. rhamnosus GG for AAD prevention and L. reuteri for infantile colic based on moderate-quality evidence.

Evidence by Condition

ConditionStudied DoseEvidence
Antibiotic-associated diarrhea prevention10-20 billion CFU L. rhamnosus GG dailyStrong
IBS symptoms10 billion CFU L. plantarum 299v dailyStrong
Infantile colic100 million CFU L. reuteri DSM 17938 dailyStrong
Full Probiotics (Lactobacillus) Guide

References

  1. (). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews. DOI
  2. (). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World Journal of Gastroenterology. DOI